Related Experiment Video

Updated: Jun 27, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

Therapeutic modulation of KIT ligand in melanocytic disorders with implications for mast cell diseases

Alec Sevilla1,2, James Grichnik3,4

  • 1Department of Dermatology, New York Medical College, New York, New York, USA.

Experimental Dermatology
|May 7, 2024
PubMed

Insights

The KIT ligand/KIT pathway regulates melanocytes and mast cells. Targeting this pathway offers therapeutic potential for skin conditions like vitiligo, melanoma, and mastocytosis.

Area of Science:

  • Dermatology and cell signaling research.

Background:

  • The KIT ligand (KL) and its receptor KIT are crucial regulators of melanocyte and mast cell function.
  • Dysregulation of the KL/KIT pathway is implicated in various pigmentary disorders and mast cell-related diseases.
  • Understanding KL/KIT pathway regulation is key for developing targeted therapies.

Purpose of the Study:

  • To review the role of the KIT ligand/KIT pathway in cutaneous diseases.
  • To explore regulators of this pathway in skin and germ cell systems.
  • To present potential therapeutic strategies for melanocytic and mast cell disorders.

Main Methods:

  • Literature review of the KIT ligand/KIT pathway.
  • Analysis of pathway associations with cutaneous conditions.
  • Examination of regulatory mechanisms in skin and germ cells.
  • Identification of exogenous agents modulating the pathway.

Main Results:

  • The KL/KIT pathway controls melanocyte and mast cell survival, migration, proliferation, and activation.
  • Pathway blockade causes cell depletion; overactivation leads to mastocytosis or melanoma.
  • Expression defects are linked to pigmentary and mast cell disorders.
  • The review covers pathway regulators and exogenous agents.

Conclusions:

  • The KIT ligand/KIT pathway is a significant target for treating melanocytic and mast cell disorders.
  • Potential therapeutic applications include vitiligo, hair greying, melasma, urticaria, mastocytosis, and melanoma.
  • Further research into pathway modulation may yield novel treatments for these conditions.
Keywords:
KITKIT ligandmast cellsmelanocytespigmentation

More Related Videos

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice09:07

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

10.4K
Feeder-free Derivation of Melanocytes from Human Pluripotent Stem Cells12:21

Feeder-free Derivation of Melanocytes from Human Pluripotent Stem Cells

Published on: March 3, 2016

10.3K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
901
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518